Access
To read this story in full you will need to login or make a payment (see right).
Correspondence
Nature Medicine 11, 817 - 818 (2005)
doi:10.1038/nm0805-817b
Killing pain, not neurons
Barbara G Sahagan1, Diane T Stephenson2, Neil Hounslow3, Dane R Liston1 & Pamela T Manning4
- Pfizer Global Research & Development, CNS Discovery, Groton, Connecticut 06340, USA.
- WW Safety Sciences, Groton/New London Labs, Sandwich, UK CT13 9NJ.
- Clinical Development, Sandwich, UK CT13 9NJ.
- Discovery Biology, St. Louis, Missouri 63017, USA.
Correspondence to: Barbara G Sahagan1 e-mail: barbara.g.sahagan@pfizer.com
In their recent paper, Kukar et al.1 studied the effects of a number of drugs on beta-amyloid (A
) production in wild-type mice and a mouse model of A deposition. They conclude that there are therapeutic agents that may augment A42 production and thereby increase the risk of Alzheimer disease in individuals on long-term therapy with such drugs.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive ImpairmentNeuropsychopharmacology Original Article
Diverse compounds mimic Alzheimer disease?causing mutations by augmenting Aβ42 productionNature Medicine Article (01 Jun 2005)
